ArticleJournal for immunotherapy of cancer2023

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release.

Eunhee Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.